Therma Bright Inc. provided an update on its partnership with Inretio Inc. Inretio recently announced promising results for its PREVATM mechanical thrombectomy device for ischemic stroke treatment. The device has been undergoing a Good Laboratory Practice (GLP) animal study, at the Shamir Medical Center's Research Unit, which is world renowned for its innovation research in Israel. The study is progressing as planned, demonstrating the PREVATM device's ability to remove 100% of a blood clot in 85% of the cases.

The results of the GLP study are a positive sign for the device's future development and potential regulatory approval and commercialization. The study is expected to be completed during the second quarter of 2023, at which point Inretio plans to submit the data, as well as mechanical verification and validation (V&V) testing data, to the Israeli Ministry of Health for Clinical Trial clearance in humans, which will be a significant milestone towards commercialization. Current mechanical solutions are based on stents that open inside the clot without aspiration, often resulting in fragmentation of the clot, which can lead to the creation of new blockages downstream and cause secondary damage to the brain tissue.

Even a minor reduction and blood flow during the procedure can have a significant impact on the patient's future quality of life. The PREVATM device is designed to mechanically remove blood clots in the brain, which is a critical factor in the treatment of ischemic stroke. It is the first and only protective clot retriever that uses a distal basket.

The device's unique PREVATM basket "ensnares" the clot, encapsulating it and protecting the brain from any sub-clots breaking off during the thrombectomy procedure. This ensures the complete removal of the clot and its fragments, leading to more successful revascularization of the brain which can prevent further damage and complications and potentially improve patient outcomes.